Soren SPAC Targets $220M IPO, Healthcare Focus Amid Dilution Concerns

TL;DR

**SORNU's IPO is a high-risk bet on management's ability to find a unicorn in healthcare, but the sponsor's cheap founder shares mean public investors are starting way behind.**

AI Summary

Soren Acquisition Corp. (SORNU) filed an S-1/A on December 19, 2025, for an initial public offering of 22,000,000 units at $10.00 per unit, aiming to raise $220,000,000. Each unit comprises one Class A ordinary share and one-third of one redeemable warrant. The SPAC intends to focus on the healthcare industry for its initial business combination, which must be completed within 24 months of the offering's close. Soren Holdings LLC, the sponsor, purchased 8,433,333 Class B ordinary shares for a nominal $25,000, or $0.003 per share, and committed to buying 4,670,000 private warrants for $4,670,000. Public shareholders face immediate and substantial dilution due to the sponsor's low-cost founder shares and potential dilution from up to 5,000,000 private warrants and an additional 1,500,000 private warrants if working capital loans of up to $1,500,000 are converted. Management and advisors, including CEO Arghavan Di Rezze with an indirect interest in 3,879,333 founder shares, also hold indirect interests in founder shares, creating potential conflicts of interest. The company will pay an affiliate of its sponsor $25,000 monthly for administrative services.

Why It Matters

This S-1/A filing signals Soren Acquisition Corp.'s intent to raise significant capital for a healthcare-focused SPAC, potentially introducing a new player into a competitive sector. Investors face substantial dilution risks from the sponsor's low-cost founder shares and private warrants, which could impact returns even if a business combination is successful. Employees and customers of a potential target company could see changes in operations and strategic direction post-acquisition. The broader market will watch to see if Soren can identify and successfully merge with a compelling healthcare target, especially given the current SPAC market dynamics and the 24-month deadline.

Risk Assessment

Risk Level: high — The risk level is high due to significant potential dilution for public shareholders, as the sponsor purchased 8,433,333 Class B ordinary shares for a nominal $0.003 per share. Additionally, the sponsor and management's indirect interests in founder shares create conflicts of interest, incentivizing them to complete a transaction even if it's unprofitable for public shareholders, especially given the 24-month deadline to consummate an initial business combination.

Analyst Insight

Investors should carefully evaluate the substantial dilution risks and potential conflicts of interest before considering an investment in SORNU. Given the nominal cost basis of the sponsor's shares, a wait-and-see approach until a definitive business combination target is identified and thoroughly vetted would be prudent.

Financial Highlights

revenue

$0

operating Margin

N/A

total Assets

$220,000,000

total Debt

$0

net Income

$0

eps

$0.00

gross Margin

N/A

cash Position

$220,000,000

revenue Growth

N/A

Executive Compensation

Key Numbers

• $220,000,000 — Total offering size (Proposed capital to be raised from 22,000,000 units at $10.00 each)
• 22,000,000 — Units offered (Number of units in the initial public offering)
• $10.00 — Price per unit (Offering price for each unit)
• 24 months — Time to complete business combination (Deadline from closing of offering to consummate initial business combination)
• 8,433,333 — Class B ordinary shares purchased by sponsor (Number of founder shares acquired by Soren Holdings LLC)
• $25,000 — Purchase price for founder shares (Aggregate amount paid by sponsor for Class B ordinary shares)
• $0.003 — Price per founder share (Cost per Class B ordinary share for the sponsor)
• 4,670,000 — Private warrants purchased by sponsor (Number of private warrants committed for purchase by Soren Holdings LLC)
• $1.00 — Price per private warrant (Purchase price for each private warrant)
• $25,000 — Monthly administrative services fee (Amount paid to an affiliate of the sponsor for office space and support)

Key Players & Entities

• Soren Acquisition Corp. (company) — Registrant for S-1/A filing
• Soren Holdings LLC (company) — Sponsor of Soren Acquisition Corp.
• Arghavan Di Rezze (person) — Chief Executive Officer of Soren Acquisition Corp., with indirect interest in 3,879,333 founder shares
• Jamie Weber (person) — Chief Financial Officer of Soren Acquisition Corp., with indirect interest in 50,000 founder shares
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for S-1/A filing
• BTIG (company) — Representative of the underwriters
• Nasdaq Stock Market LLC (company) — Intended listing exchange for SORNU units
• Reed Smith LLP (company) — Legal counsel for the registrant
• Ellenoff Grossman & Schole LLP (company) — Legal counsel for the registrant
• Walkers (Cayman) LLP (company) — Cayman Islands legal counsel for the registrant

FAQ

Risk Factors

• Dilution from Sponsor Shares and Warrants [high — financial]: Public shareholders face immediate and substantial dilution due to the sponsor's purchase of 8,433,333 Class B ordinary shares at $0.003 per share. Further dilution may occur from up to 5,000,000 private warrants and an additional 1,500,000 private warrants if working capital loans are converted.
• Limited Time for Business Combination [medium — operational]: The SPAC has a strict 24-month deadline from the offering's close to complete an initial business combination. Failure to do so will result in the dissolution of the company and return of funds to public shareholders, impacting potential returns.
• Sponsor Warrants and Potential Conversion [medium — financial]: The sponsor committed to buying 4,670,000 private warrants at $1.00 each. An additional 1,500,000 private warrants could be issued if working capital loans are converted, increasing the potential dilution for public shareholders.
• Administrative Services Fee [low — financial]: An affiliate of the sponsor will receive a $25,000 monthly fee for administrative services. This ongoing expense reduces the capital available for the business combination and impacts the SPAC's cash burn rate.
• Conflicts of Interest [medium — legal]: Management and advisors, including the CEO, hold indirect interests in founder shares. This creates potential conflicts of interest that may not align with the best interests of public shareholders during the business combination process.
• Healthcare Industry Focus [medium — market]: The SPAC's intention to focus on the healthcare industry subjects it to the specific risks and regulatory environments of this sector, including rapid technological changes, reimbursement policies, and clinical trial outcomes.

Industry Context

Soren Acquisition Corp. is targeting the healthcare industry, a sector characterized by rapid innovation, significant regulatory oversight (e.g., FDA approvals), and complex reimbursement landscapes. Key trends include advancements in biotechnology, digital health solutions, and personalized medicine. The competitive landscape is dynamic, with established pharmaceutical giants, agile biotech startups, and other SPACs vying for attractive acquisition targets.

Regulatory Implications

As a SPAC, Soren Acquisition Corp. is subject to SEC regulations governing public offerings and ongoing reporting requirements. The healthcare focus also means potential targets will face stringent FDA regulations, data privacy laws (like HIPAA), and evolving healthcare policies, all of which can impact a target's valuation and operational viability.

What Investors Should Do

1. Review Sponsor Economics
2. Monitor Target Industry and Deal Terms
3. Assess Management's Conflict of Interest Mitigation
4. Factor in Ongoing Administrative Costs

Key Dates

• 2025-12-19: S-1/A Filing — Initiated the public offering process, providing details on the SPAC's structure, objectives, and risks.

Glossary

SPAC

Special Purpose Acquisition Company. A shell company that raises capital through an IPO to acquire an existing company. (Soren Acquisition Corp. is a SPAC seeking a target for a business combination.)

Units

A combination of securities sold together in an offering, typically including shares and warrants. (The offering consists of 22,000,000 units, each with one Class A ordinary share and one-third of a warrant.)

Redeemable Warrants

Options that give the holder the right to purchase a share of stock at a specified price within a certain timeframe. (Included in the units, these warrants can be exercised by public shareholders, potentially increasing dilution.)

Class B Ordinary Shares

Shares typically held by the sponsor, often with different voting rights and conversion terms compared to Class A shares. (The sponsor holds 8,433,333 Class B shares acquired at a nominal cost, leading to significant dilution for public investors.)

Founder Shares

Shares issued to the SPAC's founders or sponsor at a nominal price before the IPO. (Equivalent to Class B ordinary shares in this filing, they represent a significant portion of the sponsor's investment and dilute public shareholders.)

Private Warrants

Warrants purchased by the sponsor or other private investors concurrently with the IPO, often at a different price than public warrants. (The sponsor is purchasing 4,670,000 private warrants, with potential for more, adding to dilution.)

Business Combination

The acquisition or merger of the SPAC with a target operating company. (The primary objective of Soren Acquisition Corp., which must be completed within 24 months.)

Dilution

The reduction in the ownership percentage of existing shareholders due to the issuance of new shares or securities that are convertible into shares. (A major concern for public investors due to the sponsor's low-cost shares and warrants.)

Year-Over-Year Comparison

As this is an S-1/A filing for an initial public offering, there is no prior year filing to compare against. Key metrics such as revenue, net income, and margins are not applicable at this pre-IPO stage. The filing primarily outlines the proposed offering structure, the sponsor's economics, the SPAC's investment strategy, and associated risks, with the primary focus being the $220,000,000 capital raise.

Key Financial Figures

• $220,000,000 — O COMPLETION, DATED DECEMBER 19, 2025 $220,000,000 Soren Acquisition Corp. 22,000,000
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one Class A ordinary sh
• $11.50 — ne Class A ordinary share at a price of $11.50 per share, subject to adjustment as des
• $25,000 — ares for an aggregate purchase price of $25,000 (up to 1,100,000 of which are subject t
• $0.003 — ponsor purchased the founder shares for $0.003 per share. The Class B ordinary shares
• $1,500,000 — y experience material dilution if up to $1,500,000 in working capital loans are fully adva
• $1.00 — capital loans into private warrants at $1.00 per warrant, resulting in the sponsor r
• $300,000 — ring or thereafter, we will repay up to $300,000 in loans made to us by our sponsor to c
• $100,000 — us for permitted withdrawals and up to $100,000 of interest income to pay dissolution e
• $0.10 — 217,800,000 ____________ (1) Includes $0.10 per unit, or $2,200,000 in the aggregat
• $2,200,000 — ______ (1) Includes $0.10 per unit, or $2,200,000 in the aggregate (or $2,530,000 in the
• $2,530,000 — nit, or $2,200,000 in the aggregate (or $2,530,000 in the aggregate if the underwriters' o
• $253,000,000 — ed in this prospectus, $220,000,000, or $253,000,000 if the underwriters' overallotment opti

Filing Documents

• ea0260278-02.htm (S-1/A) — 4146KB
• ea026027802ex1-1_soren.htm (EX-1.1) — 248KB
• ea026027802ex1-2_soren.htm (EX-1.2) — 50KB
• ea026027802ex3-2_soren.htm (EX-3.2) — 299KB
• ea026027802ex4-1_soren.htm (EX-4.1) — 16KB
• ea026027802ex4-2_soren.htm (EX-4.2) — 16KB
• ea026027802ex5-1_soren.htm (EX-5.1) — 18KB
• ea026027802ex5-2_soren.htm (EX-5.2) — 39KB
• ea026027802ex10-1_soren.htm (EX-10.1) — 43KB
• ea026027802ex10-2_soren.htm (EX-10.2) — 91KB
• ea026027802ex10-3_soren.htm (EX-10.3) — 110KB
• ea026027802ex10-4_soren.htm (EX-10.4) — 42KB
• ea026027802ex10-5_soren.htm (EX-10.5) — 111KB
• ea026027802ex10-8_soren.htm (EX-10.8) — 10KB
• ea026027802ex14-1_soren.htm (EX-14.1) — 59KB
• ea026027802ex23-1_soren.htm (EX-23.1) — 2KB
• ea026027802ex99-1_soren.htm (EX-99.1) — 49KB
• ea026027802ex99-2_soren.htm (EX-99.2) — 35KB
• ex5-1_001.jpg (GRAPHIC) — 8KB
• ex5-2_001.jpg (GRAPHIC) — 3KB
• ex5-2_002.jpg (GRAPHIC) — 2KB
• ex10-2_001.jpg (GRAPHIC) — 4KB
• ex10-2_002.jpg (GRAPHIC) — 11KB
• 0001213900-25-123582.txt ( ) — 8810KB
• ck0002086263-20251219.xsd (EX-101.SCH) — 9KB
• ck0002086263-20251219_def.xml (EX-101.DEF) — 15KB
• ck0002086263-20251219_lab.xml (EX-101.LAB) — 108KB
• ck0002086263-20251219_pre.xml (EX-101.PRE) — 65KB
• ea0260278-02_htm.xml (XML) — 1072KB

Risk factors

Risk factors 47 Cautionary note regarding forward-looking statements 96

Use of proceeds

Use of proceeds 97 Dividend policy 100

Dilution

Dilution 101 Capitalization 103

Management's discussion and analysis of financial condition and results of operations

Management's discussion and analysis of financial condition and results of operations 104 Proposed business 110 Effecting our initial business combination 123 Management 144 Principal shareholders 154 Certain relationships and related party transactions 157

Description of securities

Description of securities 160 Taxation 181

Underwriting

Underwriting 192 Legal matters 202 Experts 202 Where you can find additional information 202 Index to Financial Statements F-1 We

View Full Filing

View this S-1/A filing on SEC EDGAR